• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Publication relating to transparency notifications

    12/20/24 4:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care
    Get the next $NYXH alert in real time by email

                   

    REGULATED INFORMATION

    Publication relating to transparency notifications

    Mont-Saint-Guibert (Belgium), December 20, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

    BlackRock, Inc.

    On December 19, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons. Based on the notification, BlackRock, Inc. (together with its controlled undertakings) holds 1,124,630 voting rights, consisting of 1,122,658 shares and 1,972 equivalent financial instruments, representing 3.00% of the total number of voting rights on December 17, 2024 (37,427,265).

    The notification dated December 18, 2024 contains the following information:

    • Reason for the notification:
      • Acquisition or disposal of voting securities or voting rights
      • Acquisition or disposal of financial instruments that are treated as voting securities
    • Notification by: a parent undertaking or a controlling person
    • Persons subject to the notification requirement:
      • BlackRock, Inc. (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
      • BlackRock Advisors, LLC (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
      • BlackRock Financial Management, Inc. (with address at 50 Hudson Yards, New York, NY, 10001, U.S.A.)
      • BlackRock Fund Advisors (with address at 400 Howard Street, San Francisco, CA, 94105, U.S.A.)
      • BlackRock Institutional Trust Company, National Association (with address at 400 Howard Street, San Francisco, CA, 94105, U.S.A.)
      • BlackRock Investment Management (UK) Limited (with address at 12 Throgmorton Avenue, London, EC2N 2DL, U.K.)
      • BlackRock Investment Management, LLC (with address at 1 University Square Drive, Princeton, NJ, 8540, U.S.A.)
    • Date on which the threshold was crossed: December 17, 2024
    • Threshold that is crossed: 3%
    • Denominator: 37,427,265
    • Notified details:
    A) Voting rightsPrevious notificationAfter the transaction
     # of voting rights# of voting rights% of voting rights
    Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
    BlackRock, Inc.00 0.00% 
    BlackRock Advisors, LLC1,038,3611,089,161 2.91% 
    BlackRock Financial Management, Inc.06,167 0.02% 
    BlackRock Fund Advisors446255 0.00% 
    BlackRock Institutional Trust Company, National Association02,551 0.01% 
    BlackRock Investment Management (UK) Limited1,0801,080 0.00% 
    BlackRock Investment Management, LLC25,23423,444 0.06% 
    Subtotal1,065,121 1,122,658 3.00% 
     TOTAL1,122,65803.00%0.00%



    B) Equivalent financial instrumentsAfter the transaction
    Holders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
    BlackRock Fund AdvisorsSecurities Lent  2000.00%physical
    BlackRock Financial Management, Inc.Contract Difference  1,7720.00%cash
     TOTAL  1,9720.01% 



     TOTAL (A & B)# of voting rights% of voting rights 
        1,124,6303.00% 
    • Full chain of controlled undertakings through which the holding is effectively held:



    BlackRock, Inc.

    BlackRock Finance, Inc.

    Trident Merger, LLC

    BlackRock Investment Management, LLC

    BlackRock, Inc.

    BlackRock Finance, Inc.

    BlackRock Holdco 2, Inc.

    BlackRock Financial Management, Inc.

    BlackRock International Holdings, Inc.

    BR Jersey International Holdings L.P.

    BlackRock Holdco 3, LLC

    BlackRock Cayman 1 LP

    BlackRock Cayman West Bay Finco Limited

    BlackRock Cayman West Bay IV Limited

    BlackRock Group Limited

    BlackRock Finance Europe Limited

    BlackRock Investment Management (UK) Limited

    BlackRock, Inc.

    BlackRock Finance, Inc.

    BlackRock Holdco 2, Inc.

    BlackRock Financial Management, Inc.

    BlackRock Holdco 4, LLC

    BlackRock Holdco 6, LLC

    BlackRock Delaware Holdings Inc.

    BlackRock Institutional Trust Company, National Association

    BlackRock, Inc.

    BlackRock Finance, Inc.

    BlackRock Holdco 2, Inc.

    BlackRock Financial Management, Inc.

    BlackRock Holdco 4, LLC

    BlackRock Holdco 6, LLC

    BlackRock Delaware Holdings Inc.

    BlackRock Fund Advisors

    BlackRock, Inc.

    BlackRock Finance, Inc.

    BlackRock Holdco 2, Inc.

    BlackRock Financial Management, Inc.

    BlackRock, Inc.

    BlackRock Finance, Inc.

    BlackRock Holdco 2, Inc.

    BlackRock Financial Management, Inc.

    BlackRock Capital Holdings, Inc.

    BlackRock Advisors, LLC

    • Additional information: The disclosure obligation arose due to total holdings in voting rights for BlackRock, Inc. going above 3%. Please note that the actual percentage in section 10 (A) is 2.99%. The form displays it as remaining at 3% due to the rounding of the form.



    *

    * *

    Contact:

    Nyxoah

    John Landry, CFO

    [email protected]

    Attachment

    • 2024 12 19 PR Transparency notification 2024 10 (BlackRock) (ENG)


    Primary Logo

    Get the next $NYXH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NYXH

    DatePrice TargetRatingAnalyst
    7/31/2023Buy
    H.C. Wainwright
    7/19/2023Neutral
    Robert W. Baird
    4/21/2022$30.00Outperform
    Oppenheimer
    4/6/2022$21.00Peer Perform
    Wolfe Research
    12/21/2021$47.00Overweight
    Cantor Fitzgerald
    7/28/2021$43.00Overweight
    Cantor Fitzgerald
    7/28/2021$40.00Overweight
    Piper Sandler
    7/27/2021$43.00Buy
    Stifel
    More analyst ratings

    $NYXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Nyxoah SA

      SC 13D/A - Nyxoah SA (0001857190) (Subject)

      10/10/24 4:00:17 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Nyxoah SA (Amendment)

      SC 13D/A - Nyxoah SA (0001857190) (Subject)

      5/30/24 5:20:40 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Nyxoah SA (Amendment)

      SC 13G/A - Nyxoah SA (0001857190) (Subject)

      2/14/24 4:17:59 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Nyxoah S.A.

      H.C. Wainwright initiated coverage of Nyxoah S.A. with a rating of Buy

      7/31/23 8:05:01 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Robert W. Baird initiated coverage on Nyxoah S.A.

      Robert W. Baird initiated coverage of Nyxoah S.A. with a rating of Neutral

      7/19/23 7:19:37 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Oppenheimer initiated coverage on Nyxoah S.A. with a new price target

      Oppenheimer initiated coverage of Nyxoah S.A. with a rating of Outperform and set a new price target of $30.00

      4/21/22 7:16:59 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025

      Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results that day beginning 2:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's

      5/7/25 4:30:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Conditional Issuance of Shares

      INSIDE INFORMATIONREGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), today announced a conditional issuance of up to 5 million ordinary shares under its existing at-the-market equity offering programs (the "ATM"). This brings the aggregate number of ordinary shares that can be sold and issued under the Company's ATM to 5,662,694 (the "ATM Shares"), which includes 662,694 shares that are still available from the conditional issuance of shares under the ATM decided upon on December 22, 2022. Pursuant to the existing sales agreement entered into

      4/16/25 2:00:00 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Provides Update on FDA Approvable Letter for Genio System

      Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), which develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an update on the FDA approval process for the Genio system. On March 26, 2025, the Company announced that the U.S. Food and Drug Administration (FDA) issued an Approvable Letter regarding the Company's Pre-Market Approval (PMA) application for the Genio® system. The Approvable L

      4/8/25 1:00:00 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Leadership Updates

    Live Leadership Updates

    See more
    • Nyxoah Appoints John Landry as Chief Financial Officer

      Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. Mr. Landry

      11/4/24 4:45:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Appoints Scott Holstine as Chief Commercial Officer

      Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch. Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by

      7/15/24 2:00:00 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Strengthens its Executive Leadership Team

      Nyxoah Strengthens its Executive Leadership TeamFrancis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah's Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device

      11/28/23 4:30:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Financials

    Live finance-specific insights

    See more
    • Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025

      Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results that day beginning 2:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's

      5/7/25 4:30:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results

      REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating ResultsFDA PMA Application Review Nearing ConclusionPositioned for U.S. Commercial Launch in March 2025 Mont-Saint-Guibert, Belgium – March 13, 2024, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the fourth quarter and financial year 2024.   Recent Financial and Operating Highlights Revenue for the fourth quarter of 2024 was €1.3 million, which excludes €0.6 million of deferred rev

      3/13/25 2:00:00 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025

      Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025 Mont-Saint-Guibert, Belgium – Monday, March 10, 2025, 10:05pm CET / 5:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and financial year 2024 on Thursday, March 13, 2025. Company management will host a conference call to discuss financial results that day beginning 1:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxo

      3/10/25 5:05:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    SEC Filings

    See more
    • SEC Form 6-K filed by Nyxoah SA

      6-K - Nyxoah SA (0001857190) (Filer)

      4/16/25 6:00:43 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Nyxoah SA

      6-K - Nyxoah SA (0001857190) (Filer)

      4/8/25 6:02:10 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Nyxoah SA

      EFFECT - Nyxoah SA (0001857190) (Filer)

      4/2/25 12:15:23 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care